Logo image of GERN

GERON CORP (GERN) Stock Fundamental Analysis

NASDAQ:GERN - Nasdaq - US3741631036 - Common Stock - Currency: USD

1.39  -0.04 (-2.8%)

After market: 1.42 +0.03 (+2.16%)

Fundamental Rating

3

GERN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 549 industry peers in the Biotechnology industry. GERN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GERN is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

GERN had negative earnings in the past year.
GERN had a negative operating cash flow in the past year.
GERN had negative earnings in each of the past 5 years.
In the past 5 years GERN always reported negative operating cash flow.
GERN Yearly Net Income VS EBIT VS OCF VS FCFGERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

GERN has a better Return On Assets (-15.85%) than 80.87% of its industry peers.
The Return On Equity of GERN (-33.91%) is better than 75.23% of its industry peers.
Industry RankSector Rank
ROA -15.85%
ROE -33.91%
ROIC N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
GERN Yearly ROA, ROE, ROICGERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

GERN has a better Gross Margin (97.79%) than 97.63% of its industry peers.
GERN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GERN Yearly Profit, Operating, Gross MarginsGERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

4

2. Health

2.1 Basic Checks

GERN does not have a ROIC to compare to the WACC, probably because it is not profitable.
GERN has more shares outstanding than it did 1 year ago.
GERN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, GERN has an improved debt to assets ratio.
GERN Yearly Shares OutstandingGERN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GERN Yearly Total Debt VS Total AssetsGERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -1.92, we must say that GERN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.92, GERN perfoms like the industry average, outperforming 54.46% of the companies in the same industry.
A Debt/Equity ratio of 0.46 indicates that GERN is not too dependend on debt financing.
GERN has a Debt to Equity ratio of 0.46. This is in the lower half of the industry: GERN underperforms 73.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Altman-Z -1.92
ROIC/WACCN/A
WACC9.64%
GERN Yearly LT Debt VS Equity VS FCFGERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

GERN has a Current Ratio of 7.87. This indicates that GERN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of GERN (7.87) is better than 71.22% of its industry peers.
A Quick Ratio of 6.79 indicates that GERN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.79, GERN is in the better half of the industry, outperforming 66.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.87
Quick Ratio 6.79
GERN Yearly Current Assets VS Current LiabilitesGERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

GERN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.89%, which is quite impressive.
The Revenue has grown by 11912.20% in the past year. This is a very strong growth!
The Revenue has been growing by 178.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)63.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)11912.2%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%5459.64%

3.2 Future

The Earnings Per Share is expected to grow by 40.11% on average over the next years. This is a very strong growth
Based on estimates for the next years, GERN will show a very strong growth in Revenue. The Revenue will grow by 68.70% on average per year.
EPS Next Y52.14%
EPS Next 2Y35.39%
EPS Next 3Y29.21%
EPS Next 5Y40.11%
Revenue Next Year162.93%
Revenue Next 2Y100.41%
Revenue Next 3Y78.99%
Revenue Next 5Y68.7%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
GERN Yearly Revenue VS EstimatesGERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B
GERN Yearly EPS VS EstimatesGERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GERN. In the last year negative earnings were reported.
Also next year GERN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GERN Price Earnings VS Forward Price EarningsGERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GERN Per share dataGERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as GERN's earnings are expected to grow with 29.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.39%
EPS Next 3Y29.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GERN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GERON CORP

NASDAQ:GERN (8/20/2025, 4:34:19 PM)

After market: 1.42 +0.03 (+2.16%)

1.39

-0.04 (-2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners81.82%
Inst Owner Change0.74%
Ins Owners0.08%
Ins Owner Change17.75%
Market Cap885.32M
Analysts78.75
Price Target3.46 (148.92%)
Short Float %12.12%
Short Ratio7.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.04%
Min EPS beat(2)22.38%
Max EPS beat(2)35.71%
EPS beat(4)4
Avg EPS beat(4)31.14%
Min EPS beat(4)13.34%
Max EPS beat(4)53.15%
EPS beat(8)8
Avg EPS beat(8)22.06%
EPS beat(12)10
Avg EPS beat(12)18.21%
EPS beat(16)13
Avg EPS beat(16)16.05%
Revenue beat(2)1
Avg Revenue beat(2)-8.43%
Min Revenue beat(2)-19.48%
Max Revenue beat(2)2.61%
Revenue beat(4)3
Avg Revenue beat(4)7.74%
Min Revenue beat(4)-19.48%
Max Revenue beat(4)45.76%
Revenue beat(8)6
Avg Revenue beat(8)182.19%
Revenue beat(12)7
Avg Revenue beat(12)127.18%
Revenue beat(16)10
Avg Revenue beat(16)192.72%
PT rev (1m)-8.1%
PT rev (3m)-17.84%
EPS NQ rev (1m)9.78%
EPS NQ rev (3m)-43.73%
EPS NY rev (1m)0%
EPS NY rev (3m)-21.31%
Revenue NQ rev (1m)6.08%
Revenue NQ rev (3m)-8.69%
Revenue NY rev (1m)-0.88%
Revenue NY rev (3m)-0.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.38
P/FCF N/A
P/OCF N/A
P/B 3.41
P/tB 3.41
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0.26
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.85%
ROE -33.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.79%
FCFM N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.26%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.87
Quick Ratio 6.79
Altman-Z -1.92
F-Score4
WACC9.64%
ROIC/WACCN/A
Cap/Depr(3y)94.77%
Cap/Depr(5y)125.95%
Cap/Sales(3y)140.92%
Cap/Sales(5y)119.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y52.14%
EPS Next 2Y35.39%
EPS Next 3Y29.21%
EPS Next 5Y40.11%
Revenue 1Y (TTM)11912.2%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%5459.64%
Revenue Next Year162.93%
Revenue Next 2Y100.41%
Revenue Next 3Y78.99%
Revenue Next 5Y68.7%
EBIT growth 1Y65.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.75%
EBIT Next 3Y17.69%
EBIT Next 5YN/A
FCF growth 1Y-25.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.68%
OCF growth 3YN/A
OCF growth 5YN/A